Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease

Phase 3 Enrolling by invitation 1850 enrolled United Therapeutics

NaSingle-groupOpen-labelTreatment

Summary

Study RIN-PF-302 is designed to evaluate the long-term safety and tolerability of inhaled treprostinil in subjects with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis.

Timeline

Start: 2022-09-06
Primary completion: 2026-06
Completion: 2026-06

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Treprostinil	Other / unclassified	6 ug	Inhaled

Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease

Summary

Timeline

Drugs

Indications